The combination of PI3K and MEK inhibitors has the potential to control GBM tumor growth and extend survival, yet more studies are needed to optimize beneficial effects and reduce resistance and/or toxicity in these targeted treatments. The gene discussed is MAP2K7; the disease is glioblastoma.